Monday, February 20, 2017

Drugs in Clinical Pipeline: BMS 986166 | Treatment of Ulcerative Colitis

BMS 986166 is an experimental drug being developed by Bristol-Myers Squibb for treating Ulcerative Colitis (UC). Ulcerative colitis (UC) is a long-term condition that results in inflammation and ulcers of the colon and rectum. The primary symptom of active disease is abdominal pain and diarrhea mixed with blood. Weight loss, fever, and anemia may also occur. The cause of UC is unknown. Theories involve immune system dysfunction, genetics, changes in the normal gut bacteria, and environmental factors. Dietary changes may improve symptoms. Several medications are used to treat symptoms and bring about and maintain remission. These include aminosalicylates such as sulfasalazine, steroids, immunosuppressants such as azathioprine, and biological therapy. Removal of the colon by surgery may be necessary if the disease is severe.

Treatment of Ulcerative colitis
New Drug for Treating Ulcerative Colitis

Preclinical development is ongoing, and Phase I development of an oral solution of BMS 986166 is planned in the US [1].

1. A Multiple Dose Study to Assess the Safety and Tolerability of BMS-986166 in Healthy Volunteers. NCT03038711
1 2 3